Efficacy,tolerability and safety of perampanel in children and adolescents with epilepsy: Systematic review and meta-analysis |
| |
| Institution: | 1. Department of Pediatrics, National Hospital Organization Ureshino Medical Center, Ureshino, Saga, Japan;2. Department of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan;3. Department of Neurosurgery, Faculty of Medicine, Saga University, Saga, Japan;1. Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan;2. Department of Pediatrics, School of Medicine, Iwate Medical University, Iwate, Japan;3. Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama, Japan;4. Clinical Genetics Department, Yokohama City University Hospital, Yokohama, Japan;5. Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan;1. Department of Child Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan;2. Department of Human Genetics, Yokohama City University Graduate School of Medicine, Japan;3. Division of Glycopathology, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University, Japan;4. Center for Medical Education, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Japan;5. Division of Neurology, Department of Internal Medicine, St. Marianna University School of Medicine, Japan;6. Department of Neurosurgery, National Center Hospital, National Center of Neurology and Psychiatry, Japan;7. Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry, Japan;8. Department of Laboratory Medicine, St. Marianna University, School of Medicine, Japan;9. Forefront Research Center, Graduate School of Science, Osaka University, Japan |
| |
| Abstract: | ObjectivePerampanel (PER) is a novel antiepileptic drug. The efficacy, tolerability and safety of PER in children and adolescents with epilepsy are still unclear. We aimed to study the efficacy and safety of PER in children and adolescents with epilepsy.MethodsWe searched PubMed, Embase and Cochrane Library for relevant literature up to November 2022. Then we extracted the relevant data from eligible literature for systematic review and meta-analysis.ResultTwenty-one studies involving 1968 children and adolescent patients were included. A reduction in seizure frequency of at least 50 percent occurred in 51.5% (95% confidence interval CI] 47.1%, 55.9%]) of patients. Complete seizure cessation occurred in 20.6% (95%CI 16.7%, 25.4%]). The incidence of adverse events was 40.8% (95%CI 33.8%, 48.2%]). The most common adverse events were drowsiness 15.3% (95% CI 13.7%, 16.9%]), irritability 9.3% (95%CI 8.0%, 10.6%]), dizziness 8.4% (95% CI 7.2%, 9.7%]). The incidence of drug discontinuation due to adverse events was 9.2% (95% CI 7.0%, 11.5%]).ConclusionPER is generally well tolerated and effective in the treatment of epilepsy in children and adolescents. Larger studies are still needed to explore the application of PER in children and adolescents.Risk of bias and limitationThe funnel plot suggests that there may be publication bias in our meta-analysis, and most of the included studies were Asian, so there may be some racial differences. |
| |
| Keywords: | Epilepsy Perampanel Efficacy Tolerability Safety |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
